SOMERVILLE, Mass., May 10, 2023 (GLOBE NEWSWIRE) — Finch Therapeutics Group, Inc. (“Finch”, “Finch Therapeutics” or the “Company”) (Nasdaq: FNCH), a microbiome technology company with a portfolio of intellectual property and microbiome assets, today reported first quarter 2023 financial results and provided business updates. “Finch has continued to execute on…Read More
Finch Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates
